Cybin Inc. (NEO: CYBN.NE) AI-Powered Stock Analysis
See how Cybin Inc. scores across key metrics like financial growth, valuation, and market position on the NEO, using AI-driven evaluation.
CYBN.NE●NEO
HealthcareMedical - Pharmaceuticals
$10.84
$0.08(0.73%)
Canadian Market opens in 21h 18m
Cybin Inc. (NEO: CYBN.NE) AI-Powered Stock Analysis
See how Cybin Inc. scores across key metrics like financial growth, valuation, and market position on the NEO, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerCybin Inc. (NEO: CYBN.NE) Stock Overall Grade
Cybin Inc.'s grade for its NEO listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Cybin Inc.'s overall NEO stock rating.
Forecast
C+Score
52/100Financial Growth
CScore
40/100Fundamental Growth
CScore
48/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
C+Score
50/100Cybin Inc. (NEO: CYBN.NE) AI-Powered Stock Analysis
On the NEO, CYBN.NE demonstrates Normal performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (48/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NEO-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(NEO: CYBN.NE) Component Analysis Explained
Understand the key factors behind each Cybin Inc. (NEO: CYBN.NE) stock grade, including financials, comparisons, and forecasts.